Health care stocks were advancing premarket Friday, with The Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.4% higher.
Halozyme Therapeutics (HALO) shares were up over 11% after the company said it has withdrawn its proposal to acquire Evotec (EVO) for 11 euro ($11.47) per share in cash. Evotec shares were down past 20% pre-bell.
Eyenovia (EYEN) shares were over 9% higher after the company said Avenue Capital Management has agreed to support a potential restructuring of Eyenovia's loan and security agreement, and defer principal and interest payments on its outstanding debt until the end of February 2025.
Amneal Pharmaceuticals (AMRX) shares advanced by over 4% after the company said US regulators have approved its exenatide formulation as an adjunct treatment to help control glucose levels in the bloodstream of adults with type 2 diabetes mellitus.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。